Conflict of interest: Nothing to declare.
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program†
Version of Record online: 2 JUL 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 4, pages 633–641, April 2013
How to Cite
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., Houghton, P. J., Smith, M. A. and Lock, R. B. (2013), Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 60: 633–641. doi: 10.1002/pbc.24235
- Issue online: 13 FEB 2013
- Version of Record online: 2 JUL 2012
- Manuscript Accepted: 24 MAY 2012
- Manuscript Received: 25 APR 2012
- National Cancer Institute. Grant Numbers: NO1-CM-42216, CA21765, CA108786
Additional Supporting Information may be found in the online version of this article.
|pbc_24235_sm_SuppResponse.doc||145K||Supplemental Response Definitions|
|pbc_24235_sm_SuppFig1.tif||9252K||Supplemental Figure 1|
|pbc_24235_sm_SuppTab1.docx||154K||Supplemental Table 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.